Indeed, SPRY2 promoter hypermethylation is correlated with decreased SPRY2 expression levels in several cancers, including hepatocellular carcinoma [19], B-cell lymphoma [20], endometrial carcinoma [21], and prostate cancer [22]. This evidence concerns the gene SPRY2 and prostate carcinoma.